Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Spinal Muscular Atrophy Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

25 Apr, 2019, 13:39 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, April 25, 2019 /PRNewswire/ --

Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028)

  • Spinal Muscular Atrophy total prevalent population was 19,343 in 7 major markets in 2017.
  • Spinal Muscular Atrophy total diagnosed prevalent population in 7 major markets was 17,094 in 2017
  • The total diagnosed cases in the United States are 11,733 cases.

DelveInsight launched Spinal Muscular Atrophy Market Insights, Epidemiology and Market Forecast- 2028. 

  1. Spinal Muscular Atrophy market report covers a descriptive overview and comprehensive insight of the SMA epidemiology and Spinal Muscular Atrophy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. SMA market report provides the insights on the current and emerging spinal muscular atrophy therapies.
  3. SMA market report provides global historical and forecasted market covering drug outreach in 7 MM.
  4. Spinal Muscular Atrophy market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the SMA market.

Get a free sample page­­­: https://bit.ly/­­­­2IQmWjo

 "Spinal Muscular Atrophy types are SMA Type 0, SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4; where the majority (three-fourth) of Spinal Muscular Atrophy prevalent population belongs to Spinal Muscular Atrophy Type 2 and SMA Type 3"

Coming to Spinal Muscular Atrophy treatment, the current US market is dominated by the employment of symptomatic treatment comprising focus on Nutrition, Respiratory Care Assessment, Respiratory Muscle Weakness, Orthopedic Care, Rehabilitation, along with few medications. Few off-label alternatives considers Valproic acid that is found to offer minor improvement in some SMA patients but is no longer recommended due to serious side effects. Few molecules are also found to be associated with SMA diagnosis as off-label therapies.

Spinal Muscular Atrophy market is expected to show positive growth, mainly attributed to increased SMA diagnosed prevalence and also, the launch of upcoming SMA therapies during the forecast period. The current SMA market hold Spinraza as the only approved drug for the management of Spinal Muscular Atrophy. Expected Launch of potential therapies may increase Spinal Muscular Atrophy market size in the coming years.

The key SMA market players have a potential to create a significant positive shift in the Spinal Muscular Atrophy Market Size. Some of companies involved are:-

  1. Novartis
  2. Astellas Pharma
  3. Hoffmann-La Roche
  4. Catalyst Pharmaceuticals

Spinal Muscular Atrophy market will increase in the upcoming years with the emergence of several upcoming SMA therapies like:

  1. Zolgensma (AVXS-101)
  2. Risdiplam (RG7916)
  3. Reldesemtiv (CK-2127107)
  4. Branaplam (LMI070)

Get a free demo of the report: https://bit.ly/2IQmWjo

Table of contents

1.   SMA Key Insights

2.   Spinal Muscular Atrophy Market Overview at a Glance

3.    Spinal Muscular Atrophy Disease Background and Overview

4.    Spinal Muscular Atrophy Epidemiology and Patient Population

5.    Spinal Muscular Atrophy Country Wise-Epidemiology

5.1.   United States

5.2.   EU5 Countries

5.3.   Germany

5.4.   France

5.5.   Italy

5.6.   Spain

5.7.   United Kingdom

5.8.   Japan

6.    Spinal Muscular Atrophy Treatment

7.    Spinal Muscular Atrophy Treatment Algorithm

8.    United States Association Current Recommendations for Spinal Muscular Atrophy (Guidelines)

9.    Europe Association Current Recommendations for Spinal Muscular Atrophy

10.  Japan Association Current Recommendations for Spinal Muscular Atrophy

11.  SMA Unmet Needs

12.  Spinal Muscular Atrophy Marketed Drugs

13.  SMA Emerging Drugs

13.1.   Key Cross Competition

13.2.   Zolgensma: Novartis

13.3.   Risdiplam: Hoffmann-La Roche

13.4.   Reldesemtiv: Astellas Pharma/Cytokinetics

13.5.   Branaplam: Novartis

13.6.   Amifampridine Phosphate: Catalyst Pharmaceuticals

13.7.   BVS 857: Novartis

14.  Spinal Muscular Atrophy 7 Major Market Analysis

15.  The United States Market Outlook

16.   EU-5 Countries: Market Outlook

16.1.   Germany

16.2.   France

16.3.   Italy

16.4.   Spain

16.5.   United Kingdom

17.    Japan Market Outlook

18.    SMA Market Drivers

19.     SMA Market Barriers

20.     Appendix

21.     DelveInsight Capabilities

22.     Disclaimer

23.     About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related reports:

Spinal Muscular Atrophy (SMA) - Pipeline Insight, 2019 – This report outlays comprehensive insights of present development scenario and growth prospects across Spinal Muscular Atrophy (SMA). A detailed picture of the SMA pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2028 - The report provides a comprehensive analysis of the Spinal Muscular Atrophy (SMA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Logo- https://mma.prnewswire.com/media/776895/DelveInsight_Logo.jpg

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.